Adaptive inhibitors of the HIV-1 protease
- PMID: 15572155
- DOI: 10.1016/j.pbiomolbio.2004.07.005
Adaptive inhibitors of the HIV-1 protease
Abstract
A significant obstacle to the efficacy of drugs directed against viral targets is the presence of amino acid polymorphisms in the targeted molecules. Amino acid polymorphisms may occur naturally due to the existence of variations within and between viral strains or as the result of mutations associated with drug resistance. An ideal drug will be one that is extremely effective against a primary target and maintains its effectiveness against the most important variations of the target molecule. A drug that simultaneously inhibits different variants of the target will lead to a faster suppression of the virus, retard the appearance of drug-resistant mutants and provide more efficacious and, in the long range, more affordable therapies. Drug molecules with the ability to inhibit several variants of a target with high affinity have been termed adaptive drugs (Nat. Biotechnol. 20 (2002) 15; Biochemistry 42 (2003) 8459; J. Cell. Biochem. S37 (2001) 82). Current drug design paradigms are predicated upon the lock-and-key hypothesis, which emphasizes shape complementarity as a way to attain specificity and improved binding affinity. Shape complementarity is accomplished by the introduction of conformational constraints in the drug molecule. While highly constrained molecules do well against a unique target, they lack the ability to adapt to target variations like those originating from naturally occurring polymorphisms or drug-resistant mutations. Targeting an array of closely related targets rather than a single one while still maintaining selectivity, requires a different approach. A plausible strategy for designing high affinity adaptive inhibitors is to engineer their most critical interactions (for affinity and specificity) with conserved regions of the target while allowing for adaptability through the introduction of flexible asymmetric functionalities in places facing variable regions of the target. The fundamental thermodynamics and structural principles associated with this approach are discussed in this chapter.
Similar articles
-
Protein promiscuity: drug resistance and native functions--HIV-1 case.J Biomol Struct Dyn. 2005 Jun;22(6):615-24. doi: 10.1080/07391102.2005.10531228. J Biomol Struct Dyn. 2005. PMID: 15842167
-
Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors.Prog Biophys Mol Biol. 2005 Jun;88(2):209-31. doi: 10.1016/j.pbiomolbio.2004.07.001. Prog Biophys Mol Biol. 2005. PMID: 15572156 Review.
-
Thermodynamic rules for the design of high affinity HIV-1 protease inhibitors with adaptability to mutations and high selectivity towards unwanted targets.Int J Biochem Cell Biol. 2004 Sep;36(9):1787-99. doi: 10.1016/j.biocel.2004.02.021. Int J Biochem Cell Biol. 2004. PMID: 15183345 Review.
-
A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.Proteins. 2004 May 15;55(3):594-602. doi: 10.1002/prot.20069. Proteins. 2004. PMID: 15103623
-
A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.Biochemistry. 2003 Jan 28;42(3):631-8. doi: 10.1021/bi027019u. Biochemistry. 2003. PMID: 12534275
Cited by
-
Thermodynamics of T-cell receptor-peptide/MHC interactions: progress and opportunities.J Mol Recognit. 2008 Jul-Aug;21(4):275-87. doi: 10.1002/jmr.896. J Mol Recognit. 2008. PMID: 18496839 Free PMC article. Review.
-
Efficient Entropy-Driven Inhibition of Dipeptidyl Peptidase III by Hydroxyethylene Transition-State Peptidomimetics.Chemistry. 2021 Oct 7;27(56):14108-14120. doi: 10.1002/chem.202102204. Epub 2021 Aug 31. Chemistry. 2021. PMID: 34314529 Free PMC article.
-
Accurate Prediction of Inhibitor Binding to HIV-1 Protease Using CANDOCK.Front Chem. 2022 Jan 17;9:775513. doi: 10.3389/fchem.2021.775513. eCollection 2021. Front Chem. 2022. PMID: 35111726 Free PMC article.
-
Adding calorimetric data to decision making in lead discovery: a hot tip.Nat Rev Drug Discov. 2010 Jan;9(1):23-7. doi: 10.1038/nrd3054. Epub 2009 Dec 4. Nat Rev Drug Discov. 2010. PMID: 19960014 Review.
-
Enthalpy screen of drug candidates.Anal Biochem. 2016 Nov 15;513:1-6. doi: 10.1016/j.ab.2016.08.023. Epub 2016 Aug 25. Anal Biochem. 2016. PMID: 27567994 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous